Michael Peel / Financial Times:
AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci’s AI tech for large-scale protein analysis to find a viable cancer therapy — Deal with Absci is the most recent between huge pharma and tech corporations to construct new illness therapies
